What Is Substance P and What Is Its Role in the Body?

Substance P is a small signaling molecule, just eleven amino acids long, that acts as both a neurotransmitter and a hormone-like messenger across a surprisingly wide range of body systems. First identified in the 1930s from brain and gut tissue extracts, it earned the uninspiring name “P” simply because it was found in a powder preparation. Despite the bland label, substance P turns out to be one of the most versatile chemical messengers in the body, with established roles in pain, inflammation, mood, digestion, immune defense, and tissue repair, among others. Its influence reaches so many organs that blocking its primary receptor has become a real pharmacological strategy, already used in hospitals to prevent nausea after chemotherapy and surgery.

How Substance P Sends Its Signals

Substance P belongs to a family of peptides called tachykinins, named for their ability to rapidly contract smooth muscle. It is produced from a larger precursor protein encoded by the preprotachykinin-A gene, which is expressed in neurons throughout the brain, spinal cord, and peripheral nervous system, as well as in certain immune and gut cells.¹ Once released, substance P preferentially binds to the neurokinin-1 receptor (NK1R), a receptor embedded in cell membranes in the brain, spinal cord, gut wall, skin, airways, and blood vessels.²

When substance P docks onto the NK1R, it triggers a cascade inside the cell. The receptor activates internal signaling proteins, causing a rise in intracellular calcium and, in some cases, an increase in a second messenger called cyclic AMP. These signals can alter how the cell behaves: a neuron may fire more readily, an immune cell may release inflammatory chemicals, or a smooth muscle cell may contract. Research has shown that when enzymes in tissue trim a few amino acids off the front end of substance P, the resulting fragments can still raise calcium levels but lose the ability to boost cyclic AMP, meaning the body’s own metabolism of the peptide subtly reshapes its effects.³ Those trimmed fragments can also activate an entirely different receptor on mast cells, adding another layer of complexity to how the body responds to substance P and its breakdown products.⁴

Pain Transmission

The role most people associate with substance P is pain. When you stub your toe or burn your finger, sensory nerve fibers carry pain signals from the injury site toward the spinal cord. Substance P is released at the spinal end of those fibers, where it helps relay the pain message to second-order neurons that send it onward to the brain.² In this context, substance P acts as an amplifier: it does not just pass the signal along, it can make neurons in the spinal cord more sensitive to future painful input, a process that contributes to chronic pain states where the nervous system seems to overreact to stimuli that should not hurt as much as they do.

Substance P’s pain pathway intersects with the body’s own painkilling system in a direct, physical way. Mu-opioid receptors, the targets of drugs like morphine and fentanyl, frequently sit on the very same neurons that carry NK1 receptors. In the trigeminal region of the brainstem, roughly a third of neurons expressing NK1R also carry mu-opioid receptors.⁵ This co-location means opioids can directly counteract substance P’s excitatory effects on the same cell, rather than needing to block it at a distance. More recent work has revealed that substance P does not just coexist with the opioid system but actively reshapes it: through NK1R signaling, substance P can speed up the recycling of mu-opioid receptors back to the cell surface after they have been used, effectively re-sensitizing the cell to opioids. In mice, this cross-regulation enhanced the pain-relieving effect of fentanyl but not morphine, hinting that different opioid drugs interact with the substance P system in different ways.⁶

Neurogenic Inflammation and the Immune System

Pain and inflammation are closely linked, and substance P sits squarely at their intersection. When sensory nerves in tissue are activated, they do not just send messages to the brain. They also release substance P and a related peptide called CGRP locally, triggering what researchers call neurogenic inflammation. This peptide release causes nearby mast cells to dump histamine, which widens blood vessels, increases blood flow, and allows fluid and immune cells to flood into the tissue.⁷ The result is the familiar redness, swelling, and warmth you see around an injury or an allergic reaction.

Beyond this local inflammatory role, substance P has a broader conversation with immune cells throughout the body. It can stimulate human blood monocytes to produce key inflammatory signaling molecules, including interleukin-1, tumor necrosis factor-alpha, and interleukin-6, at very low concentrations.⁸ Nerve-derived substance P also influences how fast immune cells multiply and how aggressively they respond, essentially giving the nervous system a direct line of communication into the immune system.⁹ Recent research has even shown that sensory nerves detecting allergens on the skin can release neuropeptides, potentially including substance P, that help kick-start the allergic immune response itself, suggesting the nervous system is not merely reacting to inflammation but actively helping to initiate it.¹⁰

Gut Function and Inflammatory Bowel Disease

The gastrointestinal tract is one of the richest sources of substance P in the body. Nerve fibers lining the gut release it to help regulate smooth muscle contraction, fluid secretion, and blood flow in the intestinal wall. This makes substance P a key player in what scientists call the brain-gut axis, the bidirectional communication between the central nervous system and the digestive system.¹¹

When this system goes awry, substance P appears to contribute to the inflammation seen in conditions like ulcerative colitis and Crohn’s disease. Studies of colon tissue from patients with ulcerative colitis have found markedly more substance P nerve fibers in the intestinal lining compared to healthy tissue, with the increase scaling with disease severity.¹² Patients with active Crohn’s disease show elevated substance P levels in both blood plasma and colon tissue compared with patients in remission and healthy controls, and the degree of elevation tracks with disease activity.¹¹ Whether substance P is a cause of the inflammation, a consequence of it, or both is still being sorted out, but the correlation is strong enough that researchers consider it a potential target for future therapies.

Nausea and Anti-Emetic Drugs

One of the most successful clinical applications of substance P research has nothing to do with pain. It involves nausea. Substance P acts within the brainstem’s vomiting center, and its presence there makes the NK1 receptor a compelling drug target for preventing nausea and vomiting. Aprepitant, the first NK1 receptor antagonist approved for clinical use, crosses the blood-brain barrier and blocks substance P’s action in the emetic pathways.¹³

Aprepitant is now commonly given to cancer patients undergoing chemotherapy to prevent both the immediate and the delayed waves of nausea that these drugs cause. It has also been studied extensively for postoperative nausea and vomiting, where it has shown promise because it targets a pathway that older anti-nausea drugs, like serotonin blockers, do not fully cover.¹⁴ For patients who do not respond adequately to standard anti-nausea medications, NK1 antagonists represent a genuinely different mechanism of action rather than just another variation on the same theme.

Stress, Anxiety, and Depression

Substance P is one of the most abundant peptides in brain regions that regulate emotion, including the amygdala and the septum. Stressful or threatening experiences reliably increase substance P release in these areas, and the magnitude of the increase tracks with how severe the stressor is.¹⁵ In rat studies, immobilization stress triggered a long-lasting increase in substance P release of about 150% in the medial amygdala. When researchers then tested the animals’ anxiety-like behavior, immobilized rats were measurably more anxious, and injecting an NK1 receptor blocker into the amygdala reversed that effect.¹⁶

These findings have led to the idea that blocking the NK1 receptor might help treat anxiety and depression in humans. In one early double-blind clinical trial, an NK1 receptor antagonist called MK-869 showed significant antidepressant activity compared to placebo in patients with major depression and moderate anxiety, with fewer sexual side effects than the conventional antidepressant paroxetine.¹⁷ Despite that promising start, subsequent larger trials of NK1 antagonists as standalone antidepressants produced mixed results, and no NK1 blocker has been approved specifically for depression. The biology is clearly there, but translating it into a reliable drug has proven harder than the early results suggested.

Skin and Chronic Itch

If you have ever scratched an itchy rash and noticed it getting redder and more irritated, substance P is part of the reason. In the skin, substance P released from sensory nerve endings activates mast cells and triggers the cascade of neurogenic inflammation. For people with chronic itch conditions like chronic prurigo, this is not just a passing nuisance: substance P and NK1R levels are measurably elevated in both the blood and the affected skin compared to healthy individuals.¹⁸

Because substance P sits at the crossroads of nerve signaling, immune activation, and skin inflammation, targeting it pharmacologically makes intuitive sense for itch. A topical form of aprepitant (the same NK1 blocker used for nausea) has been tested in chronic prurigo patients as a proof-of-concept. Meanwhile, the metabolic fragments of substance P add a wrinkle: some fragments activate mast cells through a completely different receptor, while others may have anti-inflammatory effects through pathways that are not yet fully understood.⁴ The implication is that measuring total substance P levels in the skin may not tell the full story; what matters is the balance between the intact peptide and its various breakdown products.

Blood Vessels and Blood Pressure

Substance P is a potent vasodilator. When injected into the forearm, it widens blood vessels and increases local blood flow, an effect mediated entirely through the NK1 receptor. In clinical experiments, an NK1 receptor antagonist blocked this vasodilation in a dose-dependent manner. However, blocking the NK1 receptor under resting conditions did not change baseline blood flow, blood pressure, or heart rate, indicating that substance P does not play a major role in maintaining normal vascular tone moment to moment.¹⁹

Where substance P’s vascular effects become more interesting is in certain forms of high blood pressure. In rat models of salt-dependent hypertension, blocking the NK1 receptor produced sustained increases in blood pressure, suggesting that substance P was actively working to keep blood pressure from climbing even higher. In contrast, blocking the receptor had little effect in forms of hypertension that were not salt-dependent or in animals with normal blood pressure.²⁰ This suggests substance P may serve as a partial safety valve specifically during salt-driven blood pressure elevation.

Wound Healing and Tissue Repair

Given its pro-inflammatory reputation, it may seem counterintuitive that substance P helps wounds heal. But controlled inflammation is actually a necessary first step in tissue repair, and substance P appears to orchestrate part of that early inflammatory burst. In animal models, applying substance P to skin wounds improved healing, while animals lacking either substance P or its receptor showed impaired wound closure.²¹

The mechanism involves macrophages, the immune cells that clean up damaged tissue and coordinate repair. Substance P treatment shifted macrophages toward a repair-promoting state, sometimes called the M2 phenotype, which helps build new tissue rather than destroying old tissue. This is particularly relevant in diabetes, where chronic wounds are a serious clinical problem. Diabetic skin often has reduced nerve fiber density, meaning less substance P is available locally. Supplementing it in animal models of diabetic wound healing improved outcomes, raising the possibility that substance P-based topical treatments could eventually help patients with non-healing diabetic ulcers.

Links to Cancer

One of the more unexpected areas of substance P research involves cancer. Tumor cells from many different cancer types express both substance P and high levels of the NK1 receptor, often at levels exceeding those found in the corresponding normal tissue. The more aggressive the tumor’s characteristics, the more NK1 receptors it tends to express.²² When substance P activates these receptors, it can promote tumor cell proliferation, encourage the cells to migrate, and stimulate the growth of new blood vessels to feed the tumor.²³

In laboratory experiments, NK1 receptor antagonists have been able to inhibit tumor cell growth and trigger cancer cell death through apoptosis, and they block both the migration of tumor cells and the formation of new blood vessels. This is still largely preclinical work, and no NK1 antagonist is approved as a cancer treatment. But the consistency of the findings across many tumor types has kept interest alive. The fact that aprepitant, a drug already in clinical use for nausea, also blocks the same receptor makes it a convenient candidate for repurposing studies, though the doses needed for anti-tumor effects may be very different from those used for nausea prevention.

Airways and Cough

The respiratory system has its own relationship with substance P. Sensory nerves in the airways release it in response to irritants, and it contributes to bronchoconstriction, the tightening of airway smooth muscle that makes breathing difficult during an asthma attack. Inflammatory signals like interleukin-1 beta can increase the amount of substance P in airway neurons, amplifying the airway’s tendency to overreact to irritants.²⁴

The connection to cough is more nuanced. In guinea pig experiments, inhaled substance P caused significant bronchoconstriction at high doses but did not directly trigger coughing.²⁵ Yet blocking the NK1 receptor inhibited coughing triggered by other stimuli like histamine or allergens, and in human studies, aerosolized substance P did not provoke cough in healthy people but did cause coughing in patients with respiratory infections.²⁶ The likely explanation is that substance P enhances the cough reflex when the airway lining is already damaged or inflamed, rather than triggering cough on its own in a healthy airway. Normally, an enzyme called neutral endopeptidase in the airway epithelium quickly breaks down substance P, keeping its effects in check. When the epithelium is damaged by infection or irritation, this protective breakdown slows, and substance P accumulates enough to amplify the cough response.

Neurodegenerative Disease

Substance P’s role in neurodegenerative conditions like Alzheimer’s and Parkinson’s disease is complicated because the peptide appears to cut both ways. On one hand, substance P levels are reduced in the brains and cerebrospinal fluid of patients with both diseases, and supplementing it has shown neuroprotective effects in laboratory models by influencing how amyloid precursor protein is processed.²⁷ On the other hand, substance P can also promote neuroinflammation, inhibit cellular cleanup processes like autophagy, activate mast cells in the brain, and alter blood-brain barrier permeability in ways that could worsen disease.²⁸

This “double-edged” profile makes substance P a tricky therapeutic target in neurodegeneration. Simply boosting it might help in some respects and hurt in others. Whether the neuroprotective or the neuroinflammatory effects dominate likely depends on the stage of disease and the brain region in question. For now, substance P levels in cerebrospinal fluid are being explored primarily as a biomarker that could help track disease progression, rather than as a treatment target.

Receptor Desensitization

One reason substance P’s effects are usually self-limiting rather than spiraling out of control is that the NK1 receptor has a built-in shutdown mechanism. When substance P binds the receptor and activates it, the cell quickly responds by pulling the receptor off the surface and swallowing it into internal compartments called endosomes. This process, called internalization, happens within minutes and involves a set of proteins called beta-arrestins that physically cap the receptor, stop it from signaling, and drag it inward.²⁹ The receptor and beta-arrestins remain together in endosomes for over an hour before the receptor gradually returns to the cell surface, restoring the cell’s ability to respond.³⁰

This cycle matters clinically. In chronic pain or chronic itch, where substance P is released continuously, the receptor may be repeatedly internalized and recycled, leaving it in a semi-desensitized state. Understanding this turnover has influenced the design of NK1-targeting drugs, since a drug that stays bound during recycling may behave very differently from one that is stripped off during internalization.

An Ancient Signaling System

Substance P is not a mammalian novelty. Tachykinin peptides, the family to which it belongs, are found across the animal kingdom. In vertebrates, tachykinins share a characteristic chemical signature at one end of the molecule. Invertebrates, from fruit flies to marine worms, have their own versions, tachykinin-related peptides, that differ in fine detail but use receptors descended from the same ancestral gene.³¹ In insects like fruit flies, tachykinin-related peptides regulate gut function, feeding behavior, and sensitivity to sensory stimuli, functions that are not so different from what substance P does in mammals. This conservation across hundreds of millions of years of evolution suggests that tachykinin signaling solved some fundamental biological problem early in animal history and proved too useful to discard. The shared receptor architecture between vertebrate and invertebrate tachykinin systems further supports the idea of a single ancient origin.³²

Substance P as a Biomarker

Because substance P levels rise and fall in response to pain, inflammation, and disease activity, researchers have explored whether measuring it in blood or cerebrospinal fluid could serve as an objective indicator of what a patient is experiencing. In veterinary medicine, dogs with bone fractures had serum substance P levels roughly five times higher than pain-free controls, and levels were significantly higher in fracture patients than in dogs with a less painful orthopedic condition like patellar luxation.³³ In human chronic pain patients, cerebrospinal fluid levels of substance P show a positive correlation with pain intensity, though the correlation with serum levels is weaker, and substance P concentrations do not seem to vary much with the specific underlying cause of pain. That disconnect between spinal fluid and blood levels is a practical barrier, since a blood test is far easier to perform than a spinal tap. Still, the consistent direction of the findings keeps substance P on the list of candidate biomarkers for pain research, particularly for populations that cannot verbally report their own pain levels.